Benefits
Cofactor for the antioxidant enzyme MnSOD
Manganese is a cofactor for manganese superoxide dismutase (MnSOD), an enzyme that clears reactive oxygen species. In a 124-day trial of 47 women, 15 mg a day, above the 11 mg upper limit, raised MnSOD activity in white blood cells and serum manganese. This is a single small trial of an enzyme marker, not of a health outcome.
Bone formation
Manganese is a cofactor for enzymes involved in bone formation, and 25% to 40% of the body's manganese is in bone. No trial has tested manganese alone for bone. In a 2-year trial of 59 postmenopausal women, calcium plus zinc, copper and 5 mg manganese limited spinal bone loss versus placebo, but trace minerals alone did not differ significantly.
Joint comfort in combination formulas
Manganese ascorbate is part of some glucosamine and chondroitin formulas. In a 16-week pilot crossover trial of 34 Navy men and a 6-month trial of 93 people with knee osteoarthritis, such a combination eased knee symptoms, mainly in mild to moderate cases. Manganese was never tested alone, so these results mostly reflect the other ingredients.
Amino acid and glucose metabolism
Manganese is a cofactor for arginase, part of the urea cycle that handles nitrogen from protein, and for pyruvate carboxylase, which helps the body make glucose. Human trials of manganese for blood sugar are lacking, and studies of blood manganese and diabetes disagree.
Mechanism of action
MnSOD and reactive oxygen species
Manganese is a cofactor for manganese superoxide dismutase, one of the enzymes that scavenge reactive oxygen species. White blood cell MnSOD activity rose when women took manganese supplements, so it is used as a marker of manganese exposure.
Bone formation
Manganese is a cofactor for several enzymes involved in bone formation. In animals, deficiency impairs bone formation and lowers bone density, and supplementation raises both; human data are very limited.
Metabolic enzymes and clotting
Arginase and pyruvate carboxylase depend on manganese, linking it to amino acid, glucose and carbohydrate metabolism. Manganese also plays a role in blood clotting together with vitamin K.
Absorption and balance
Adults absorb only about 1% to 5% of dietary manganese, more when intake is low and less when it is high. More than 90% of absorbed manganese leaves through bile, and higher iron status is linked to lower manganese absorption.
Clinical trials
2-year double-blind placebo-controlled trial: calcium 1,000 mg, trace minerals (zinc 15 mg, manganese 5 mg, copper 2.5 mg), both, or placebo (Strause et al. 1994, J Nutr)
59 healthy postmenopausal women, mean age 66
Spinal bone density changed by -3.53% on placebo, -1.89% on trace minerals only, -1.25% on calcium only and +1.48% on calcium plus trace minerals. The only significant group difference was calcium plus trace minerals versus placebo (P = 0.0099), so manganese's own effect cannot be separated.
124-day supplementation study: placebo, iron 60 mg, manganese 15 mg, or both daily (Davis et al. 1992, Am J Clin Nutr)
47 women
Manganese supplementation significantly raised lymphocyte MnSOD activity and serum manganese from baseline, with no change in urinary manganese or iron status. The 15 mg dose is above today's 11 mg upper limit.
16-week randomized double-blind placebo-controlled crossover pilot: glucosamine HCl 1,500 mg, chondroitin sulfate 1,200 mg and manganese ascorbate 228 mg a day (Leffler et al. 1999, Mil Med)
34 US Navy men with chronic knee or low back pain and degenerative joint disease on X-ray
Knee symptom scores (-16.3%, p = 0.05), pain on a visual scale and examination scores improved; running times did not change. The trial neither showed nor excluded a benefit for the low back. Manganese was not tested alone.
Randomized placebo-controlled 6-month trial of glucosamine HCl 1,000 mg, chondroitin sulfate 800 mg and manganese ascorbate 152 mg twice daily (Das et al. 2000, Osteoarthritis Cartilage)
93 adults with knee osteoarthritis
People with mild or moderate disease (72) improved on the Lequesne index at 4 and 6 months (52% vs 28% responders); those with severe disease (21) did not. Adverse events were similar (17% vs 19%). Manganese was not tested alone.